age1 reposted this
How do we move from lab to clinic for an aging intervention in *this* decade? I spent a lot of time thinking about this question and created a framework dubbed the longevity funnel framework (LFF) to answer it. Read the deep dive here: https://lnkd.in/g-9mU-RP
Huge day for dogs (and eventually people) everywhere 🎉🎉 Celine Halioua is a rockstar.
we've raised another $45M, led by Bain Capital Ventures, bringing total $ raised since I started Loyal 4.5 years ago to $125M This new $ fuels us to very hopefully! bring the first FDA-approved lifespan extension drug to market in 2025. We have the data, the team, and the path forward — this capital was the last puzzle piece to ensure that, if our vision is possible, we will achieve it. new investors: Bain Cap and Valor Equity Partners with existing investors doubling/tripling down including: Khosla, First Round Capital, Box Group, Quiet Capital, Collaborative Fund, Todd & Rahul, + more Raising a growth round post-ZIRP as a weird company was a great learning experience + I plan to write that up sometime soon. the tl;dr - was crucial to connect use of new capital --> milestones unlocked --> objective increase in company, value *even* in a tough market We are now running on: > earning FDA mfg, safety, + RXE approval for LOY-002 (senior dog lifespan extension) > LOY-002 market launch in 2025 > building out distribution + commercial functions for nationwide supply > cont'd development of LOY-001 (injectable) and LOY-003 (daily pill) for large dog lifespan ext Thanks WSJ for covering!
Co-founder & CBO @ Vincere Biosciences | Conquering Age-Related Decline with AI-Driven Drug Discovery
4moNice overview and very in line with how we broke the problem down at NI and Vincere. Now quite hopeful that our mitophagy enhancing molecules will slow progressive decline of brain, heart, and kidney - the 3 top failure points in aging!